Gross Profit Trends Compared: AstraZeneca PLC vs Travere Therapeutics, Inc.

AstraZeneca's Dominance in Gross Profit Growth Over Travere

__timestampAstraZeneca PLCTravere Therapeutics, Inc.
Wednesday, January 1, 20142025300000027632226
Thursday, January 1, 20152006200000097707000
Friday, January 1, 201618876000000129037000
Sunday, January 1, 201718147000000151332000
Monday, January 1, 201817154000000158719000
Tuesday, January 1, 201919463000000170104000
Wednesday, January 1, 202021318000000192195000
Friday, January 1, 202124980000000220706000
Saturday, January 1, 202231960000000204426000
Sunday, January 1, 202337771000000133788000
Monday, January 1, 202443866000000
Loading chart...

Unveiling the hidden dimensions of data

Gross Profit Trends: AstraZeneca PLC vs Travere Therapeutics, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, AstraZeneca PLC has demonstrated a robust growth trajectory in gross profit, increasing by approximately 86% from 2014 to 2023. This growth reflects AstraZeneca's strategic investments and successful product launches. In contrast, Travere Therapeutics, Inc., a smaller player, has shown a more modest increase of around 384% in the same period, albeit from a much smaller base. This disparity highlights the scale and market reach differences between the two companies. AstraZeneca's gross profit in 2023 was nearly 280 times that of Travere, underscoring its dominant market position. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the competitive dynamics and financial health of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025